Here's Why You Should Retain GEHC Stock in Your Portfolio for Now

Key Takeaways GEHC entered 2026 with a $21.8B backlog and strong enterprise deal momentum supporting growth visibility.GEHC's Pharmaceutical Diagnostics grew 12.7%, driven by contrast media demand and PET imaging adoption.GEHC faces tariff impacts, margin pressure from investments, and uneven segment and regional performance.GE HealthCare Technologies, Inc. (GEHC) is well-poised for growth in the coming quarters, courtesy of its continued focus on innovations. The optimism, led by strong fourth-quarter 2025 ...